Quick Answer
ImageneBio, Inc. reported R&D Expense of $28.52 million for fiscal year 2025.
ImageneBio, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $28.52M | -11.2% |
| 2024 | $32.11M | -46.2% |
| 2023 | $59.65M | -7.3% |
| 2022 | $64.32M | +36.5% |
| 2021 | $47.11M | +5.0% |
| 2020 | $44.85M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.56M | +300.5% | +286.5% |
| June 30, 2025 | $4.03M | -59.1% | +8.3% |
| March 31, 2025 | $3.71M | -61.5% | -4.4% |
| September 30, 2024 | $3.88M | -73.5% | -60.5% |
| June 30, 2024 | $9.83M | -35.2% | +1.9% |
| March 31, 2024 | $9.64M | -38.0% | -34.2% |
| September 30, 2023 | $14.65M | -22.3% | -3.4% |
| June 30, 2023 | $15.17M | -2.0% | -2.4% |
- ImageneBio, Inc. showed a decrease of -11.2% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, ImageneBio, Inc.’s r&d expense has declined by 36.4% (from $44.85 million to $28.52 million).
- The most recent figure is from ImageneBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: